Education
About Us
Working with TipRanks
Follow Us
IBBQ - ETF AI Analysis
Top Page
Invesco Nasdaq Biotechnology ETF (IBBQ)
Rating:65Neutral
Price Target:
$28.00
Positive Factors
Strong Top Holdings
Several key holdings, such as Insmed and Alnylam Pharma, have delivered strong year-to-date performance, driving the ETF’s gains.
Low Expense Ratio
The ETF has a very low expense ratio compared to industry averages, making it cost-effective for investors.
Focused Sector Exposure
The ETF’s heavy allocation to the health care sector provides targeted exposure to a high-growth industry.
Negative Factors
Over-Concentration in Health Care
With nearly all assets in the health care sector, the ETF is highly sensitive to industry-specific risks.
Limited Geographic Diversification
The ETF is overwhelmingly focused on U.S. companies, offering minimal exposure to international markets.
Mixed Performance Among Holdings
Some top holdings, like Regeneron and Biogen, have underperformed year-to-date, potentially dragging on overall returns.
IBBQ vs. SPDR S&P 500 ETF (SPY)
AUM49.23M
RegionNorth America
Expense Ratio0.19%
Beta0.82
IssuerInvesco
Inception DateJun 11, 2021
Dividend Yield0.81%
Asset ClassEquity
Index TrackedNASDAQ / Biotechnology
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume28,061
30 Day Avg. Volume14,887
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
34.18Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering250
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
IBBQ Summary
The Invesco Nasdaq Biotechnology ETF (IBBQ) is an investment fund that focuses on companies in the biotechnology and life sciences industries. It follows the Nasdaq Biotechnology Index, which includes innovative healthcare firms working on cutting-edge treatments and technologies. Some of its top holdings are well-known companies like Gilead Sciences and Vertex Pharmaceuticals. Investors might consider IBBQ for potential growth, as biotech companies are at the forefront of medical advancements and global demand for new therapies is increasing. However, it’s important to know that this ETF is heavily tied to the health care sector, meaning its performance can be affected by changes in the biotech industry or regulatory challenges.
How much will it cost me?The Invesco Nasdaq Biotechnology ETF (IBBQ) has an expense ratio of 0.19%, meaning you’ll pay $1.90 per year for every $1,000 invested. This is lower than average for actively managed ETFs, as it tracks an index rather than requiring frequent adjustments by fund managers.
What would affect this ETF?The Invesco Nasdaq Biotechnology ETF (IBBQ) could benefit from advancements in biotechnology and pharmaceutical innovation, as well as increased global demand for cutting-edge healthcare solutions. However, it may face challenges from regulatory changes, high research and development costs, or broader economic downturns that could impact funding for biotech firms. Its focus on U.S.-based companies and heavy exposure to the healthcare sector means it is particularly sensitive to changes in government healthcare policies and drug approval processes.
IBBQ Top 10 Holdings
The Invesco Nasdaq Biotechnology ETF (IBBQ) is heavily concentrated in the health care sector, with a focus on innovative biotech and pharmaceutical companies. Alnylam Pharma and Insmed are rising stars, benefiting from strong earnings momentum and clinical breakthroughs, though their high leverage and financial risks temper enthusiasm. Meanwhile, Vertex Pharmaceuticals and Regeneron are showing mixed performance, with steady fundamentals but facing valuation concerns and neutral market sentiment. Gilead Sciences adds stability with its strategic focus on HIV and oncology. Overall, the fund leans heavily on U.S.-based biotech leaders, making it a bet on cutting-edge medical advancements.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Amgen | 8.03% | $3.73M | $181.33B | 22.06% | 77 Outperform | |
| Vertex Pharmaceuticals | 7.67% | $3.56M | $110.91B | -3.12% | 78 Outperform | |
| Gilead Sciences | 7.59% | $3.53M | $155.11B | 41.41% | 77 Outperform | |
| Regeneron | 5.94% | $2.76M | $72.89B | -5.41% | 79 Outperform | |
| Alnylam Pharma | 4.84% | $2.25M | $59.34B | 98.28% | 57 Neutral | |
| AstraZeneca | 3.83% | $1.78M | $275.88B | 41.03% | 75 Outperform | |
| Insmed | 3.39% | $1.57M | $41.21B | 196.35% | 53 Neutral | |
| Argenx Se | 2.30% | $1.07M | $55.65B | 63.69% | 79 Outperform | |
| Biogen | 2.04% | $946.66K | $24.58B | 5.95% | 74 Outperform | |
| United Therapeutics | 1.75% | $812.47K | $20.08B | 31.38% | 79 Outperform |
IBBQ Technical Analysis
Positive
―
Price Trends
25.48
Positive
24.05
Positive
22.58
Positive
Market Momentum
0.65
Negative
76.40
Negative
87.91
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IBBQ, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 26.69, equal to the 50-day MA of 25.48, and equal to the 200-day MA of 22.58, indicating a bullish trend. The MACD of 0.65 indicates Negative momentum. The RSI at 76.40 is Negative, neither overbought nor oversold. The STOCH value of 87.91 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IBBQ.
IBBQ Peer Comparison
Comparison Results
Performance Comparison
IBBQ
Invesco Nasdaq Biotechnology ETF
27.98
6.06
27.65%
SBIO
ALPS Medical Breakthroughs ETF
―
―
―
XHS
SPDR S&P Health Care Services ETF
―
―
―
LFSC
F/M Emerald Life Sciences Innovation ETF
―
―
―
BBP
Virtus LifeSci Biotech Products ETF
―
―
―
BBC
Virtus LifeSci Biotech Clinical Trials ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents